William Winthrop Increases Holdings in Healthcare and Consumer Staples Published: June 2020

In the first half of 2020, global markets experienced dramatic volatility unseen in decades due to the impact of the pandemic. Investors were generally uneasy and confused, fearing both a deep recession caused by the economic shutdown and a fear of missing out on a potential rebound. Against this backdrop, William Winthrop chose to review his portfolio structure and allocate more funds to the healthcare and consumer staples sectors, seeking certainty amidst uncertainty.

The continued spread of the pandemic made him realize that traditional cyclical sectors would struggle to regain earnings momentum in the short term, while the healthcare and consumer staples sectors, owing to their rigid demand, demonstrated unique resilience. Winthrop believed this was not merely a defensive choice but a forward-looking bet on the accelerating shift in global consumption and health trends. In numerous internal discussions, he emphasized that the capital flows during market panic had validated these sectors’ safe haven status, supported by solid fundamentals.

In the healthcare sector, he focuses on companies producing medical equipment, diagnostic reagents, and those with vaccine development capabilities. These companies became critical links in the global supply chain during the initial outbreak, and the continued influx of orders and R&D funding has ensured their future revenue and profit growth. Winthrop is particularly optimistic about leading companies with advantages in global presence and technological barriers, as they are poised to not only benefit during the pandemic but also to take a leading position in the long-term trend of upgrading public health systems.

The consumer staples sector is focused on stable demand areas such as food, household cleaning products, and personal care products. Winthrop has observed that even amidst economic lockdowns and rising unemployment, sales of these products have remained resilient, even experiencing periodic increases due to increased time spent at home. He prefers companies with strong brand power, supply chain management, and channel penetration, as these companies are better able to maintain profit margins during demand fluctuations.

To enhance the portfolio’s robustness, he adopted a phased approach, rather than a single, large-scale investment. Between April and May, he capitalized on market corrections at various stages to gradually increase the weightings of healthcare and consumer staples. This gradual increase not only diversified the risk of price fluctuations but also ensured holding value across various price ranges. He emphasized that while the pace of a market rebound is difficult to accurately predict, the structural advantages of the industry can be positioned in advance.

During this adjustment, Winthrop didn’t completely abandon other sectors. Instead, he reduced his exposure to high-uncertainty sectors like energy and aviation to free up capital for new allocations. He believes that the stable returns and low volatility of defensive sectors can act as a stabilizer for the portfolio in an unstable macro environment, preserving capital for future growth opportunities.

By June, as some epidemic data stabilized and signs of economic reopening emerged, market risk appetite rebounded, but the relative performance of the healthcare and consumer staples sectors remained resilient. Winthrop’s portfolio demonstrated remarkable drawdown control in volatile markets, providing investors with a predictable return profile amidst high uncertainty. For him, this was not just a tactical defensive adjustment, but a strategic positioning aligned with long-term trends.